license in
-
External Collaboration: The Core Engine Behind AbbVie’s Decade-Long Explosive Growth
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
-
Amgen’s BD Model: A Benchmark for Cross-Border Biotech Collaboration
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
-
【Asset Request】Chinese Pharma Seeking China Rights for Approved/Phase III Novel Drugs
If you are interested in this opportunity, please contact DrugTimes BD Team by email (BD@drugtimes.cn).
-
How Do American and European Biotech Companies Make Money Using Chinese New Drugs? Sharing Successful Cases of LIDLO, LIDMA, and LIDIPO
Welcome friends to share your views in the comments section! DrugTimes will continue to pay close attention and follow up on the reports
-
【Urgent Request】European and American biotech companies are interested in licensing drugs for PD, AD and other CNS diseases
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
-
【紧急】MNC、中国大药企、美国biotech公司希望引进ActRIIB抑制剂在研产品
如果贵公司对该机会感兴趣，请尽快与我们联系！
-
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Congratulations to Day One Biopharmaceuticals and MabCare Therapeutics!
-
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Congratulations to Roche and Ascidian Therapeutics!
-
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Congratulations! This is the latest cross-border licensing out deal by a pharma/biotech in China
-
TOP10 MNC Seeking FIC or BIC Products: IPF
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
